Le Lézard
Classified in: Health
Subject: SVY

Global Nuclear Medicine Market is projected to display a robust growth represented by a CAGR of 10.07% during 2018 - 2023


NEW YORK, Feb. 11, 2019 /PRNewswire/ -- Executive Summary
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Nuclear Medicine Market. The report analyzes the Nuclear Medicine Market By Product (Therapeutic, Diagnostic), By Diagnostics (SPECT, PET), By Therapeutics (Alpha Emitters, Beta Emitters, Brachytherapy) and By Indication (Cardiovascular Disorders, Oncological Disorders, Neurological Disorders, Others). The Nuclear Medicine Market has been analyzed By Region (North America, Europe, Asia Pacific, Rest of the World) and By Country (U.S., Canada, France, Germany, India, China, Japan and Brazil) for the historical period of 2013-2017 and the forecast period of 2018-2023.

Read the full report: https://www.reportlinker.com/p05730916

According to Azoth Analytics research report "Global Nuclear Medicine Market: Analysis By Product Type (Diagnostic, Therapeutic), By Diagnostic Nuclear Medicine Type, By Therapeutic Nuclear Medicine Type, By Indication, By Region, By Country (2019 Edition): Opportunities and Forecast (2013-2023) - By Region (North America, Europe, APAC, ROW), By Country (U.S., Canada, France, Germany, India, China, Japan, Brazil)", global market is projected to display a robust growth represented by a CAGR of 10.07% during 2018 ? 2023.

The indication segment of Oncological disorders has been witnessing growth at a noteworthy rate over the past few years backed by increased prevalence of cancer, presence of technical advance PET and SPECT equipment to perform treatment, rising number of nuclear centers Amongst the regions, North America accounts for the largest regional share in the global nuclear medicine market in 2018. Key factors driving the robust growth rate of North America region include well developed healthcare infrastructure, favorable regulatory reforms, rising prevalence of chronic ailment such as cardiovascular disorders, neurological disorders etc. in the region.

The report titled "Global Nuclear Medicine Market: Analysis By Product Type (Diagnostic, Therapeutic), By Diagnostic Nuclear Medicine Type, By Therapeutic Nuclear Medicine Type, By Indication, By Region, By Country (2019 Edition): Opportunities and Forecast (2013-2023) - By Region (North America, Europe, APAC, ROW), By Country (U.S., Canada, France, Germany, India, China, Japan, Brazil)" has covered and analyzed the potential of Global Nuclear Medicine and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global nuclear medicine devices market. Additionally, the report also highlights market entry strategies for various companies across the globe.

Scope of the Report
Global Nuclear Medicine Market (Actual Period: 2013-2017, Forecast Period: 2018-2023
? Global Nuclear Medicine Market ? Size, Growth, Forecast
? By Indication (Cardiovascular Disorders, Oncological Disorders, Neurological Disorders, Others)
? By Product Type (Diagnostic, Therapeutic)
? By Diagnostic Type (SPECT, PET)
? By Therapeutic Type (Alpha Emitters, Beta emitters, Brachytherapy)

Regional Markets ? North America, Europe, APAC and Rest of the World (Actual Period: 2013-2017, Forecast Period: 2018-2023)
? Nuclear Medicine Market ? Size and Growth
? By Indication (Cardiovascular Disorders, Oncological Disorders, Neurological Disorders, Others)
? By Product Type (Diagnostic, Therapeutic)
? By Diagnostic Type (SPECT, PET)
? By Therapeutic Type (Alpha Emitters, Beta emitters, Brachytherapy)

Country Analysis - U.S., Canada, Germany, United Kingdom, India, Japan China, Brazil)
? Nuclear Medicine Market ? Size and Growth
? By Indication (Cardiovascular Disorders, Oncological Disorders, Neurological Disorders, Others)

Other Report Highlights
? Market Dynamics ? Drivers and Restraints
? Market Trends
? Porter Five Force Analysis
? Policy and Regulatory Landscape
? Competitive Landscape
? Company Analysis ? Bracco Imaging, Lantheus Holding, Curium, Jubilant Lifesciences, 3B Pharmaceutical Cardinal Health Advanced Accelerator Application, Eckert & Ziegler

Customization of the Report
The report could be customized according to the client's specific research requirements. No additional cost will be required to pay for limited additional research.

Read the full report: https://www.reportlinker.com/p05730916

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

19 avr 2024
Remedium Healthcare Products is proud to announce the launch of NuVeria Labs' revolutionary Sacral Silicone Dressing, now available for purchase on Amazon, bringing advanced wound care solutions directly to consumers' doorsteps. Designed to address...

19 avr 2024
Getting specialty medications into...

19 avr 2024
Arthrex, a global leader in minimally invasive surgical technology, has once again taken home prestigious medals for product innovation at the 37th annual Edison Awards. "This product, along with our other innovations,...

19 avr 2024
Aligned with the trend of immersive water therapy in 2024, Baros Maldives' Serenity Spa stands out as an oasis of indulgent spa and beauty rituals, boasting a 50-year legacy of luxury. Nestled within a tranquil sanctuary amidst the lush Maldivian...

19 avr 2024
Oragenics, Inc. , a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated April...

19 avr 2024
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...



News published on and distributed by: